Cargando...
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer
The aims of this phase I study were to establish the maximum tolerated dose, safety profile and activity of liposomal daunorubicin, DaunoXome (NeXstar Pharmaceuticals), in the treatment of metastatic breast cancer. DaunoXome was administered intravenously over 2 h in 21 day cycles and doses were inc...
Gardado en:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group
2002
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2364277/ https://ncbi.nlm.nih.gov/pubmed/12085249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600344 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|